A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 13, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

March 31, 2019

Conditions

TuberculosisDrug-Induced Liver InjuryAdverse Drug Event

Interventions

DRUG

Isoniazid

One of the first line anti-tubercolosis drug

Trial Locations (1)

Seoul National University Hospital Clinical Trials Center, Seoul

All Listed Sponsors

collaborator

Ministry of Health & Welfare, Korea

OTHER_GOV

lead

Seoul National University Hospital

OTHER

NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status | Biotech Hunter | Biotech Hunter